LUC00197I2 - - Google Patents

Download PDF

Info

Publication number
LUC00197I2
LUC00197I2 LU00197C LUC00197C LUC00197I2 LU C00197 I2 LUC00197 I2 LU C00197I2 LU 00197 C LU00197 C LU 00197C LU C00197 C LUC00197 C LU C00197C LU C00197 I2 LUC00197 I2 LU C00197I2
Authority
LU
Luxembourg
Prior art keywords
sub
sup
kinase
fak
cdk
Prior art date
Application number
LU00197C
Other languages
English (en)
French (fr)
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9886703&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00197(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of LUC00197I1 publication Critical patent/LUC00197I1/fr
Publication of LUC00197I2 publication Critical patent/LUC00197I2/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
    • C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
    • C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
    • C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
    • C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
    • C04B35/632—Organic additives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Ceramic Engineering (AREA)
  • Manufacturing & Machinery (AREA)
  • Health & Medical Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Structural Engineering (AREA)
  • Materials Engineering (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Hydrogenated Pyridines (AREA)
  • Saccharide Compounds (AREA)
LU00197C 2000-03-01 2021-02-23 LUC00197I2 (index.php)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0004887.6A GB0004887D0 (en) 2000-03-01 2000-03-01 Chemical compounds
PCT/GB2001/000829 WO2001064656A1 (en) 2000-03-01 2001-02-26 2,4,di(hetero-)arylamino(-oxy)-5-substituted pyrimidines as antineoplastic agents

Publications (2)

Publication Number Publication Date
LUC00197I1 LUC00197I1 (index.php) 2021-02-23
LUC00197I2 true LUC00197I2 (index.php) 2021-07-05

Family

ID=9886703

Family Applications (1)

Application Number Title Priority Date Filing Date
LU00197C LUC00197I2 (index.php) 2000-03-01 2021-02-23

Country Status (25)

Country Link
US (2) US6838464B2 (index.php)
EP (1) EP1278735B1 (index.php)
JP (2) JP2003525279A (index.php)
KR (2) KR20020075463A (index.php)
CN (1) CN1220684C (index.php)
AT (1) ATE472537T1 (index.php)
AU (2) AU3397901A (index.php)
BE (1) BE2021C507I2 (index.php)
BR (1) BR0108879A (index.php)
CA (1) CA2398887C (index.php)
CY (2) CY1111093T1 (index.php)
DE (1) DE60142469D1 (index.php)
DK (1) DK1278735T3 (index.php)
ES (1) ES2346288T3 (index.php)
FR (1) FR21C1010I2 (index.php)
GB (1) GB0004887D0 (index.php)
HK (1) HK1053111B (index.php)
IL (2) IL150920A0 (index.php)
LU (1) LUC00197I2 (index.php)
MX (1) MXPA02007581A (index.php)
NO (2) NO325443B1 (index.php)
NZ (1) NZ520502A (index.php)
PT (1) PT1278735E (index.php)
WO (1) WO2001064656A1 (index.php)
ZA (1) ZA200206192B (index.php)

Families Citing this family (173)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2002523498A (ja) 1998-08-29 2002-07-30 アストラゼネカ・アクチエボラーグ ピリミジン化合物
AU5438299A (en) 1998-08-29 2000-03-21 Astrazeneca Ab Pyrimidine compounds
GB9828511D0 (en) 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
MXPA03002297A (es) * 2000-09-15 2003-06-06 Vertex Pharma Compuestos de triazol utiles como inhibidores de proteina cinasa.
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP2311825B1 (en) 2000-12-21 2015-10-07 Novartis AG Pyrimidineamines as angiogenesis modulators
ES2375491T3 (es) 2000-12-21 2012-03-01 Vertex Pharmaceuticals Incorporated Compuestos de pirazol útiles como agentes inhibidores de las prote�?na-quinasas.
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
CA2451128A1 (en) * 2001-06-26 2003-01-09 Bristol-Myers Squibb Company N-heterocyclic inhibitors of tnf-alpha expression
US7638522B2 (en) * 2001-08-13 2009-12-29 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
JO3429B1 (ar) 2001-08-13 2019-10-20 Janssen Pharmaceutica Nv مشتقات برميدينات مثبطة فيروس الايدز
US8101629B2 (en) * 2001-08-13 2012-01-24 Janssen Pharmaceutica N.V. Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile
WO2003026666A1 (en) * 2001-09-26 2003-04-03 Bayer Pharmaceuticals Corporation 2-phenylamino-4- (5-pyrazolylamino)-pyrimidine derivatives as kinase inhibitors, in particular, as src kinase inhibitors
WO2003040141A1 (en) * 2001-09-28 2003-05-15 Bayer Pharmaceuticals Corporation Oxazolyl-phenyl-2,4-diamino-pyrimidine compounds and methods for treating hyperproliferative disorders
WO2003033495A1 (en) * 2001-10-17 2003-04-24 Ucb, S.A. Quinuclidine derivatives, processes for preparing them and their uses as m2 and/or m3 muscarinic receptor inhibitors
EP1438053B1 (de) 2001-10-17 2008-09-10 Boehringer Ingelheim Pharma GmbH & Co.KG Pyrimidinderivate, arzneimittel enthaltend diese verbindungen, deren verwendung und verfahren zu ihrer herstellung
WO2003032994A2 (de) 2001-10-17 2003-04-24 Boehringer Ingelheim Pharma Gmbh & Co. Kg 5-substituierte 4-amino-2-phenylamino-pyrimidinderivate und ihre verwendung als beta-amyloid modulatoren
US8853266B2 (en) * 2001-12-06 2014-10-07 University Of Tennessee Research Foundation Selective androgen receptor modulators for treating diabetes
SE0104140D0 (sv) * 2001-12-07 2001-12-07 Astrazeneca Ab Novel Compounds
WO2003055489A1 (en) * 2001-12-21 2003-07-10 Bayer Pharmaceuticals Corporation 2,4-diamino-pyrimidine derivative compounds as inhibitors of prolylpeptidase, inducers of apoptosis and cancer treatment agents
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
ES2437391T3 (es) * 2002-02-06 2014-01-10 Vertex Pharmaceuticals, Inc. Compuestos de heteroarilo útiles como inhibidores de GSK-3
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
WO2003076434A1 (en) 2002-03-09 2003-09-18 Astrazeneca Ab 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
EP1485380B1 (en) * 2002-03-15 2010-05-19 Vertex Pharmaceuticals Incorporated Azolylaminoazines as inhibitors of protein kinases
GB0206215D0 (en) 2002-03-15 2002-05-01 Novartis Ag Organic compounds
WO2003095448A1 (en) * 2002-05-06 2003-11-20 Bayer Pharmaceuticals Corporation Pyridinyl amino pyrimidine derivatives useful for treating hyper-proliferative disorders
MY141867A (en) * 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
SI1534286T1 (sl) * 2002-07-29 2010-04-30 Rigel Pharmaceuticals Inc Postopki za zdravljenje ali prepreŽŤevanje avtoimunskih bolezni z 2,4-pirimidindiaminskimi spojinami
MXPA05001096A (es) 2002-07-29 2005-11-23 Rigel Pharmaceuticals Inc Metodos para tratamiento o prevencion de enfermedades autoinmunes con compuestos de 2,4-diamino-pirimidina.
RU2491071C2 (ru) * 2002-07-29 2013-08-27 Райджел Фармасьютикалз, Инк. Способы лечения или профилактики аутоиммунных заболеваний с помощью соединений 2,4-пиримидиндиамина
HRP20050104B1 (hr) * 2002-08-09 2014-02-14 Janssen Pharmaceutica N.V. Postupci za pripremu 4-[[4-[[4-(2-cijanoetenil)-2,6-dimetilfenil]amino]-2-pirimidinil]amino]benzonitrila
US20050282814A1 (en) * 2002-10-03 2005-12-22 Targegen, Inc. Vasculostatic agents and methods of use thereof
ATE458731T1 (de) * 2002-12-20 2010-03-15 Pfizer Prod Inc Pyrimidin-derivate zur behandlung von anormalem zellwachstum
UA80767C2 (en) * 2002-12-20 2007-10-25 Pfizer Prod Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7109337B2 (en) * 2002-12-20 2006-09-19 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
DE602004021558D1 (de) * 2003-01-17 2009-07-30 Warner Lambert Co 2-aminopyridin-substituierteheterocyclen als inhibitoren der zellulären proliferation
WO2004067516A1 (en) 2003-01-30 2004-08-12 Boehringer Ingelheim Pharmaceuticals, Inc. 2,4-diaminopyrimidine derivatives useful as inhibitors of pkc-theta
WO2004072029A2 (en) * 2003-02-06 2004-08-26 Vertex Pharmaceuticals Incorporated Pyrazolopyridazines useful as inhibitors of protein kinases
US7157455B2 (en) 2003-02-10 2007-01-02 Hoffmann-La Roche Inc. 4-Aminopyrimidine-5-one derivatives
ES2325440T3 (es) * 2003-02-20 2009-09-04 Smithkline Beecham Corporation Compuestos de pirimidina.
GB0305929D0 (en) 2003-03-14 2003-04-23 Novartis Ag Organic compounds
GB0311274D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
GB0311276D0 (en) 2003-05-16 2003-06-18 Astrazeneca Ab Chemical compounds
DK1656372T3 (da) 2003-07-30 2013-07-01 Rigel Pharmaceuticals Inc 2,4-pyrimidindiaminforbindelser til anvendelse til behandling eller forebyggelse af autoimmunsygdomme
BRPI0413616B8 (pt) 2003-08-15 2021-05-25 Irm Llc 2,4-pirimidinadiaminas, seus usos, e composição farmacêutica
GB0321710D0 (en) 2003-09-16 2003-10-15 Novartis Ag Organic compounds
US20070105839A1 (en) * 2003-09-18 2007-05-10 Patricia Imbach 2, 4-Di (phenylamino) pyrimidines useful in the treatment of proliferative disorders
AU2004283137A1 (en) 2003-10-17 2005-05-06 Astrazeneca Ab 4-(pyrazol-3-ylamino) pyrimidine derivatives for use in the treatment of cancer
GB0324551D0 (en) * 2003-10-21 2003-11-26 Karobio Ab Novel compounds
CA2548172A1 (en) * 2003-12-04 2005-06-23 Vertex Pharmaceuticals Incorporated Quinoxalines useful as inhibitors of protein kinases
TW200528101A (en) 2004-02-03 2005-09-01 Astrazeneca Ab Chemical compounds
FR2866879A1 (fr) * 2004-02-27 2005-09-02 Oreal Para-phenylenediamine secondaire n-alkylaminee, composition de teinture des fibres keratiniques contenant une telle para-phenylenediamine, procedes mettant en oeuvre cette composition et utilisations
US7338536B2 (en) 2004-02-27 2008-03-04 L'oreal S. A. N-alkylamino secondary para-phenylenediamine, composition for dyeing keratin fibers comprising such a para-phenylenediamine, processes using this composition and uses thereof
EP2543376A1 (en) 2004-04-08 2013-01-09 Targegen, Inc. Benzotriazine inhibitors of kinases
BRPI0510963A (pt) * 2004-05-14 2007-11-20 Pfizer Prod Inc derivados pirimidina para o tratamento do crescimento anormal de células
BRPI0511132A (pt) * 2004-05-14 2007-11-27 Pfizer Prod Inc derivados de pirimidina e composição farmacêutica compreendendo os mesmos
WO2005111022A1 (en) * 2004-05-14 2005-11-24 Pfizer Products Inc. Pyrimidines derivatives for the treatment of abnormal cell growth
US20060205945A1 (en) * 2004-05-14 2006-09-14 Pfizer Inc Pyrimidine derivatives for the treatment of abnormal cell growth
US7405220B2 (en) 2004-06-09 2008-07-29 Hoffmann-La Roche Inc. Pyrazolopyrimidines
EP1799656A4 (en) 2004-08-25 2009-09-02 Targegen Inc HETEROCYCLIC COMPOUNDS AND METHODS OF USE
BRPI0517737A (pt) 2004-11-17 2008-10-21 Miikana Therapeutics Inc inibidores de quinase
WO2006068770A1 (en) 2004-11-24 2006-06-29 Rigel Pharmaceuticals, Inc. Spiro-2, 4-pyrimidinediamine compounds and their uses
NZ555474A (en) * 2004-12-17 2010-10-29 Astrazeneca Ab 4-(4-(imidazol-4-yl) pyrimidin-2-ylamino) benzamides as CDK inhibitors
PL1856135T3 (pl) 2005-01-19 2010-05-31 Rigel Pharmaceuticals Inc Proleki związków 2,4-pirymidynodiaminy i ich zastosowanie
MX2007009843A (es) 2005-02-16 2007-08-23 Astrazeneca Ab Compuestos quimicos.
US20080287437A1 (en) 2005-05-16 2008-11-20 Astrazeneca Ab Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors
US20070203161A1 (en) 2006-02-24 2007-08-30 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
BRPI0606172A2 (pt) * 2005-06-08 2009-06-02 Targegen Inc métodos e composições para o tratamento de distúrbios oculares
EP1904457B1 (en) 2005-06-08 2017-09-06 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
RU2443688C2 (ru) 2005-06-28 2012-02-27 Санофи-Авентис ПРОИЗВОДНЫЕ ИЗОХИНОЛИНА В КАЧЕСТВЕ ИНГИБИТОРОВ Rho-КИНАЗЫ
KR101336678B1 (ko) 2005-07-26 2013-12-04 사노피 Ｒｈｏ-키나제 억제제로서의 사이클로헥실아민 이소퀴놀론유도체
NZ565668A (en) 2005-07-26 2010-09-30 Sanofi Aventis Piperidinyl-substituted isoquinolone derivatives as RHO-kinase inhibitors
KR20080033450A (ko) * 2005-07-30 2008-04-16 아스트라제네카 아베 증식성 질환의 치료에 사용하기 위한 이미다졸릴-피리미딘화합물
JP2009504771A (ja) * 2005-08-18 2009-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド ピラジンキナーゼ阻害剤
AU2006296386A1 (en) 2005-09-30 2007-04-05 Astrazeneca Ab Imidazo [1,2-a] pyridine having anti-cell-proliferation activity
KR101487027B1 (ko) * 2005-09-30 2015-01-28 미카나 테라퓨틱스, 인크. 치환된 피라졸 화합물
ES2391783T3 (es) 2005-10-28 2012-11-29 Astrazeneca Ab Derivados de 4-(3-aminopirazol)pirimidina para su uso como agentes inhibidores de las tirosina cinasas en el tratamiento del cáncer
ZA200804083B (en) * 2005-11-01 2009-09-30 Targegen Inc Bi-aryl meta-pyrimidine inhibitors of kinases
KR101467723B1 (ko) * 2005-11-01 2014-12-03 탈자진 인코포레이티드 키나제의 비-아릴 메타-피리미딘 억제제
US8604042B2 (en) * 2005-11-01 2013-12-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
AU2012230091B2 (en) * 2005-11-01 2015-04-23 Impact Biomedicines, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
US8133900B2 (en) * 2005-11-01 2012-03-13 Targegen, Inc. Use of bi-aryl meta-pyrimidine inhibitors of kinases
NZ606263A (en) * 2005-11-03 2014-03-28 Vertex Pharma Sliding panel suspension system
US7705009B2 (en) 2005-11-22 2010-04-27 Hoffman-La Roche Inc. 4-aminopyrimidine-5-thione derivatives
CA2634646C (en) * 2005-12-21 2012-04-10 Pfizer Products Inc. Pyrimidine derivatives for the treatment of abnormal cell growth
US7659280B2 (en) 2006-02-17 2010-02-09 Rigel Pharmaceuticals, Inc. 2,4-pyrimidinediamine compounds for treating or preventing autoimmune diseases
TW200811169A (en) * 2006-05-26 2008-03-01 Astrazeneca Ab Chemical compounds
AR063527A1 (es) 2006-10-23 2009-01-28 Cephalon Inc Derivados biciclicos fusionados de 2,4-diaminopirimidina como inhibidores de alk y c-met
EP2086965B1 (en) * 2006-11-02 2010-02-10 Vertex Pharmaceuticals, Inc. Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases
CN103641816A (zh) * 2006-12-08 2014-03-19 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
CN101616895A (zh) 2006-12-08 2009-12-30 Irm责任有限公司 作为蛋白激酶抑制剂的化合物和组合物
JP2010513567A (ja) * 2006-12-19 2010-04-30 バーテックス ファーマシューティカルズ インコーポレイテッド プロテインキナーゼの阻害剤として有用なアミノピリミジン
CA2673921C (en) 2006-12-27 2015-10-20 Sanofi-Aventis New substituted isoquinoline and isoquinolinone derivatives
CN101616909B (zh) 2006-12-27 2013-09-11 塞诺菲-安万特股份有限公司 作为Rho-激酶抑制剂的被取代的异喹啉和异喹啉酮衍生物
EP2114920A1 (en) 2006-12-27 2009-11-11 Sanofi-Aventis Substituted isoquinoline and isoquinolinone derivatives
RU2457203C2 (ru) 2006-12-27 2012-07-27 Санофи-Авентис Замещенные циклоалкиламином производные изохинолона
DE602007010981D1 (de) 2006-12-27 2011-01-13 Sanofi Aventis Cycloalkylaminsubstituierte isochinolin- und isochinolinonderivate
MX2009005964A (es) 2006-12-27 2009-06-15 Sanofi Aventis Derivados de isoquinolina sustituidos con cicloalquilamina.
AR065015A1 (es) 2007-01-26 2009-05-13 Smithkline Beecham Corp Derivados de antranilamida, composiciones farmaceuticas que los contienen, y usos para el tratamiento del cancer
NZ579483A (en) 2007-03-09 2012-07-27 Vertex Pharma Aminopyridines useful as inhibitors of protein kinases
EP2137183B1 (en) * 2007-03-09 2011-09-28 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as inhibitors of protein kinases
ES2435997T3 (es) * 2007-03-09 2013-12-26 Vertex Pharmaceuticals, Inc. Aminopirimidinas útiles como inhibidores de las proteínas cinasas
US8501763B2 (en) * 2007-03-16 2013-08-06 The Scripps Research Institute Inhibitors of focal adhesion kinase
CA2681248A1 (en) * 2007-03-20 2008-09-25 Smithkline Beecham Corporation Chemical compounds
CA2683785A1 (en) 2007-04-13 2008-10-23 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
JP4782239B2 (ja) 2007-04-18 2011-09-28 ファイザー・プロダクツ・インク 異常細胞増殖治療のためのスルホニルアミド誘導体
AU2008247595A1 (en) * 2007-05-02 2008-11-13 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
EP2152696B1 (en) * 2007-05-02 2014-09-24 Vertex Pharmaceuticals Incorporated Aminopyrimidines useful as kinase inhibitors
NZ580884A (en) * 2007-05-02 2012-02-24 Vertex Pharma Thiazoles and pyrazoles useful as kinase inhibitors
UA99459C2 (en) 2007-05-04 2012-08-27 Астразенека Аб 9-(pyrazol-3-yl)- 9h-purine-2-amine and 3-(pyraz0l-3-yl)-3h-imidazo[4,5-b]pyridin-5-amine derivatives and their use for the treatment of cancer
WO2008140724A1 (en) 2007-05-08 2008-11-20 Schering Corporation Methods of treatment using intravenous formulations comprising temozolomide
CN101687852A (zh) * 2007-05-24 2010-03-31 沃泰克斯药物股份有限公司 可用作激酶抑制剂的噻唑类和吡唑类化合物
KR101294731B1 (ko) * 2007-06-04 2013-08-16 삼성디스플레이 주식회사 어레이 기판, 이를 갖는 표시패널 및 이의 제조방법
JP2010529193A (ja) * 2007-06-11 2010-08-26 ミイカナ セラピューティクス インコーポレイテッド 置換ピラゾール化合物
WO2009010794A1 (en) * 2007-07-19 2009-01-22 Astrazeneca Ab 2,4-diamino-pyrimidine derivatives
CN101790532B (zh) * 2007-07-31 2013-11-20 沃泰克斯药物股份有限公司 5-氟-1H-吡唑并[3，4-b]吡啶-3-胺及其衍生物的制备方法
WO2009032861A1 (en) 2007-09-04 2009-03-12 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
JP2011512413A (ja) * 2008-02-19 2011-04-21 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー Ｆａｋの阻害剤としてのアニリノピリジン
PT2300013T (pt) 2008-05-21 2017-10-31 Ariad Pharma Inc Derivados de fósforo como inibidores de cinases
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
HUE026617T2 (en) 2008-06-24 2016-06-28 Sanofi Sa Substituted isoquinolines and isoquinolinones as RHO kinase inhibitors
CA2728123C (en) 2008-06-24 2017-02-21 Sanofi-Aventis Bi- and polycyclic substituted isoquinoline and isoquinolinone derivatives
ES2436531T3 (es) 2008-06-24 2014-01-02 Sanofi Isoquinolinas e isoquinolinonas sustituidas en posición 6
US11351168B1 (en) 2008-06-27 2022-06-07 Celgene Car Llc 2,4-disubstituted pyrimidines useful as kinase inhibitors
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
TWI458721B (zh) 2008-06-27 2014-11-01 Celgene Avilomics Res Inc 雜芳基化合物及其用途
WO2010027921A1 (en) * 2008-09-03 2010-03-11 Vertex Pharmaceuticals Incorporated Co-crystals and pharmaceutical formulations comprising the same
KR101705158B1 (ko) 2009-05-05 2017-02-09 다나-파버 캔서 인스티튜트 인크. Ｅｇｆｒ 억제제 및 질환 치료방법
US20120196858A1 (en) * 2009-08-12 2012-08-02 Poniard Pharmaceuticals ,Inc. Method of promoting apoptosis and inhibiting metastasis
US8466155B2 (en) * 2009-10-02 2013-06-18 Boehringer Ingelheim International Gmbh Pyrimidines
MX340819B (es) 2010-06-29 2016-07-26 Poniard Pharmaceuticals Inc * Formulacion oral de inhibidores de quinasa.
CN103168037A (zh) 2010-06-30 2013-06-19 博尼亚德医药品股份有限公司 激酶抑制剂的合成和用途
WO2012021444A1 (en) 2010-08-10 2012-02-16 Avila Therapeutics, Inc. Besylate salt of a btk inhibitor
TWI632134B (zh) 2010-11-01 2018-08-11 阿維拉製藥公司 雜環化合物及其用途
EP2635285B1 (en) 2010-11-01 2017-05-03 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
WO2012060847A1 (en) 2010-11-07 2012-05-10 Targegen, Inc. Compositions and methods for treating myelofibrosis
ES2665013T3 (es) 2010-11-10 2018-04-24 Celgene Car Llc Inhibidores de EGFR selectivos de mutante y usos de los mismos
AU2012216893B2 (en) 2011-02-17 2016-08-11 Cancer Therapeutics Crc Pty Limited FAK inhibitors
CN103534240B (zh) 2011-02-17 2015-12-09 癌症疗法Crc私人有限公司 选择性fak抑制剂
WO2012151561A1 (en) 2011-05-04 2012-11-08 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
JP2014532658A (ja) 2011-10-28 2014-12-08 セルジーン アヴィロミクス リサーチ， インコーポレイテッド ブルトン型チロシンキナーゼ疾患または障害を治療する方法
CA2866852C (en) 2012-03-15 2020-12-29 Celgene Avilomics Research, Inc. Solid forms of an epidermal growth factor receptor kinase inhibitor
RU2711077C9 (ru) 2012-03-15 2020-08-11 Селджен Кар Ллс Соли ингибитора киназы рецептора эпидермального фактора роста
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
WO2014100748A1 (en) 2012-12-21 2014-06-26 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
CN103059030B (zh) * 2012-12-28 2015-04-29 北京师范大学 一种具有粘着斑激酶抑制作用的嘧啶类化合物及其制备方法和应用
EA201591051A1 (ru) 2013-02-08 2016-06-30 Селджен Авиломикс Рисерч, Инк. Ингибиторы erk и варианты их применения
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
US9492471B2 (en) 2013-08-27 2016-11-15 Celgene Avilomics Research, Inc. Methods of treating a disease or disorder associated with Bruton'S Tyrosine Kinase
US9415049B2 (en) 2013-12-20 2016-08-16 Celgene Avilomics Research, Inc. Heteroaryl compounds and uses thereof
ES2741785T3 (es) 2014-08-13 2020-02-12 Celgene Car Llc Formas y composiciones de un inhibidor de ERK
CN106999425A (zh) 2014-09-26 2017-08-01 葛兰素史克知识产权第二有限公司 长效药物组合物
EP3715343B1 (en) * 2017-12-21 2024-02-14 Shenzhen TargetRx, Inc. Diphenylaminopyrimidine compound for inhibiting kinase activity
KR20220028075A (ko) 2019-07-03 2022-03-08 스미토모 다이니폰 파마 온콜로지, 인크. 티로신 키나제 비-수용체 1 (tnk1) 억제제 및 그의 용도
JPWO2021107066A1 (index.php) 2019-11-28 2021-06-03
CA3152105A1 (en) 2019-11-29 2021-06-03 Wai Yip Thomas Lee Composition including rilpivirine and use thereof for treating tumors or cancer
JP2023519673A (ja) 2020-03-31 2023-05-12 セラヴァンス バイオファーマ アール＆ディー アイピー， エルエルシー 置換ピリミジンおよび使用方法
CN112390760B (zh) * 2020-10-15 2022-07-29 北京师范大学 靶向fak的化合物及其制备方法和应用

Family Cites Families (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4946956A (en) 1988-09-21 1990-08-07 Uniroyal Chemical Company, Inc. Arylenediamine substituted pyrimidines
HU206337B (en) 1988-12-29 1992-10-28 Mitsui Petrochemical Ind Process for producing pyrimidine derivatives and pharmaceutical compositions
US4983608A (en) 1989-09-05 1991-01-08 Hoechst-Roussell Pharmaceuticals, Inc. N-substituted-4-pyrimidinamines and pyrimidinediamines
GB9012592D0 (en) 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
WO1992020642A1 (en) 1991-05-10 1992-11-26 Rhone-Poulenc Rorer International (Holdings) Inc. Bis mono-and bicyclic aryl and heteroaryl compounds which inhibit egf and/or pdgf receptor tyrosine kinase
US5521184A (en) 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (index.php) * 1992-04-03 1994-06-21 Ciba Geigy Ag
US5516775A (en) 1992-08-31 1996-05-14 Ciba-Geigy Corporation Further use of pyrimidine derivatives
EP0664291B1 (en) 1992-10-05 2000-07-19 Ube Industries, Ltd. Pyrimidine compound
US5612340A (en) 1993-10-01 1997-03-18 Ciba-Geigy Corporation Pyrimidineamine derivatives and processes for the preparation thereof
EP0672042B1 (en) 1993-10-01 2006-05-03 Novartis AG Pharmacologically active pyrimidineamine derivatives and processes for the preparation thereof
US5543520A (en) 1993-10-01 1996-08-06 Ciba-Geigy Corporation Pyrimidine derivatives
EP0672041B1 (en) 1993-10-01 2001-11-14 Novartis AG Pharmacologically active pyridine derivatives and processes for the preparation thereof
GB9325217D0 (en) 1993-12-09 1994-02-09 Zeneca Ltd Pyrimidine derivatives
US5750531A (en) 1994-08-13 1998-05-12 Yuhan Corporation Pyrimidine derivatives and processes for the preparation thereof
DE69630214T2 (de) 1995-03-10 2004-07-15 Berlex Laboratories, Inc., Richmond Benzamidin-derivate, deren herstellung und deren verwendung als anti-koagulantien
IL118544A (en) 1995-06-07 2001-08-08 Smithkline Beecham Corp History of imidazole, the process for their preparation and the pharmaceutical preparations containing them
US5739143A (en) 1995-06-07 1998-04-14 Smithkline Beecham Corporation Imidazole compounds and compositions
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
WO1997035856A1 (en) 1996-03-25 1997-10-02 Smithkline Beecham Corporation Novel treatment for cns injuries
AU2381397A (en) 1996-04-19 1997-11-12 Novo Nordisk A/S Modulators of molecules with phosphotyrosine recognition units
TW440563B (en) 1996-05-23 2001-06-16 Hoffmann La Roche Aryl pyrimidine derivatives and a pharmaceutical composition thereof
EP0906307B1 (en) 1996-06-10 2005-04-27 Merck & Co., Inc. Substituted imidazoles having cytokine inhibitory activity
US5780446A (en) 1996-07-09 1998-07-14 Baylor College Of Medicine Formulations of vesicant drugs and methods of use thereof
GB9619284D0 (en) 1996-09-16 1996-10-30 Celltech Therapeutics Ltd Chemical compounds
WO1998016230A1 (en) 1996-10-17 1998-04-23 Smithkline Beecham Corporation Methods for reversibly inhibiting myelopoiesis in mammalian tissue
WO1998018096A1 (en) 1996-10-23 1998-04-30 Gtn Technologies, L.L.C. Transportation reservation system
GB9622363D0 (en) 1996-10-28 1997-01-08 Celltech Therapeutics Ltd Chemical compounds
ZA9711092B (en) 1996-12-11 1999-07-22 Smithkline Beecham Corp Novel compounds.
WO1998033798A2 (en) 1997-02-05 1998-08-06 Warner Lambert Company Pyrido[2,3-d]pyrimidines and 4-amino-pyrimidines as inhibitors of cell proliferation
DE19710435A1 (de) 1997-03-13 1998-09-17 Hoechst Ag Verwendung von Pyrimidinderivaten zur Prävention von Krebs allein oder in Kombination mit anderen therapeutischen Maßnahmen
GB9705361D0 (en) 1997-03-14 1997-04-30 Celltech Therapeutics Ltd Chemical compounds
WO1998054093A1 (en) 1997-05-30 1998-12-03 Merck & Co., Inc. Novel angiogenesis inhibitors
BR9810007B1 (pt) 1997-06-12 2010-04-06 compostos, e, derivados da resina de merrifield.
TW517055B (en) 1997-07-02 2003-01-11 Smithkline Beecham Corp Novel substituted imidazole compounds
EP1019391A1 (en) 1997-10-02 2000-07-19 Merck & Co. Inc. Inhibitors of prenyl-protein transferase
WO1999018942A1 (en) 1997-10-10 1999-04-22 Imperial College Innovations Ltd. Use of csaidtm compounds for the management of uterine contractions
EP1054004B1 (en) 1997-12-15 2008-07-16 Astellas Pharma Inc. Novel pyrimidine-5-carboxamide derivatives
US6335340B1 (en) 1997-12-19 2002-01-01 Smithkline Beecham Corporation compounds of heteroaryl substituted imidazole, their pharmaceutical compositons and uses
EA200000840A1 (ru) 1998-02-17 2001-02-26 Туларик, Инк. Антивирусные производные пиримидина
AP1468A (en) 1998-03-27 2005-09-23 Janssen Pharmaceutica Nv Hiv inhibiting pyrimidine derivatives.
JP2002523498A (ja) 1998-08-29 2002-07-30 アストラゼネカ・アクチエボラーグ ピリミジン化合物
AU5438299A (en) 1998-08-29 2000-03-21 Astrazeneca Ab Pyrimidine compounds
PL346700A1 (en) 1998-09-18 2002-02-25 Basf Ag Pyrrolopyrimidines as protein kinase inhibitors
CN1326457A (zh) 1998-09-18 2001-12-12 巴斯福股份公司 作为激酶抑制剂的4－氨基吡咯并嘧啶
US6531477B1 (en) 1998-10-13 2003-03-11 Dupont Pharmaceuticals Company 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors
AU764479B2 (en) 1998-10-29 2003-08-21 Bristol-Myers Squibb Company Compounds derived from an amine nucleus that are inhibitors of IMPDH enzyme
WO2000026209A1 (en) 1998-11-03 2000-05-11 Novartis Ag Anti-inflammatory 4-phenyl-5-pyrimidinyl-imidazoles
GB9828511D0 (en) * 1998-12-24 1999-02-17 Zeneca Ltd Chemical compounds
HUP0200535A3 (en) 1999-02-01 2002-11-28 Cv Therapeutics Inc Palo Alto 2,6,9-trisubstituted purine derivatives inhibitors of cyclin dependent kinase 2 and ikappa-b-alpha and pharmaceutical compositions containing them
GB9903762D0 (en) 1999-02-18 1999-04-14 Novartis Ag Organic compounds
GB9905075D0 (en) 1999-03-06 1999-04-28 Zeneca Ltd Chemical compounds
US6627633B2 (en) 1999-03-17 2003-09-30 Albany Molecular Research, Inc. 6-substituted biaryl purine derivatives as potent cyclin/CDK inhibitors and antiproliferative agents
GB9907658D0 (en) 1999-04-06 1999-05-26 Zeneca Ltd Chemical compounds
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
CA2277689A1 (fr) 1999-07-09 2001-01-09 Krystyna Drya-Lisiecka Construction alveolaire transdynamique
GB9919778D0 (en) 1999-08-21 1999-10-27 Zeneca Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
DE60024480T2 (de) 1999-10-27 2006-07-27 Novartis Ag Thiazol und imidazo[4,5-b]pyridin verbindungen und ihre verwendung als pharmazeutika
ATE281451T1 (de) 1999-11-22 2004-11-15 Smithkline Beecham Plc Imidazolderivate und deren verwendung als raf kinase inhibitoren
CA2394727A1 (en) 1999-12-28 2001-07-05 Pharmacopeia, Inc. Pyrimidine and triazine kinase inhibitors
CN1429222A (zh) 2000-02-17 2003-07-09 安姆根有限公司 激酶抑制剂
GB0004887D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004888D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004886D0 (en) * 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0004890D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
GB0007371D0 (en) 2000-03-28 2000-05-17 Astrazeneca Uk Ltd Chemical compounds
GB0016877D0 (en) 2000-07-11 2000-08-30 Astrazeneca Ab Chemical compounds
GB0021726D0 (en) 2000-09-05 2000-10-18 Astrazeneca Ab Chemical compounds
GB0103926D0 (en) 2001-02-17 2001-04-04 Astrazeneca Ab Chemical compounds
GB0113041D0 (en) 2001-05-30 2001-07-18 Astrazeneca Ab Chemical compounds
GB0205690D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
GB0205693D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds
WO2003076434A1 (en) 2002-03-09 2003-09-18 Astrazeneca Ab 4- imidazolyl substuited pyrimidine derivatives with cdk inhibitiory activity
GB0205688D0 (en) 2002-03-09 2002-04-24 Astrazeneca Ab Chemical compounds

Also Published As

Publication number Publication date
NO20024126L (no) 2002-08-29
GB0004887D0 (en) 2000-04-19
DE60142469D1 (de) 2010-08-12
CN1220684C (zh) 2005-09-28
ZA200206192B (en) 2003-11-26
NO325443B1 (no) 2008-05-05
MXPA02007581A (es) 2002-12-13
US7067522B2 (en) 2006-06-27
JP2005041878A (ja) 2005-02-17
CA2398887A1 (en) 2001-09-07
CY1111093T1 (el) 2015-06-11
HK1053111B (en) 2011-02-18
US20050090515A1 (en) 2005-04-28
CA2398887C (en) 2008-12-16
EP1278735A1 (en) 2003-01-29
NZ520502A (en) 2004-05-28
CY2021005I1 (el) 2021-05-05
DK1278735T3 (da) 2010-08-30
PT1278735E (pt) 2010-08-12
AU3397901A (en) 2001-09-12
ES2346288T3 (es) 2010-10-14
FR21C1010I1 (index.php) 2021-05-07
KR20020075463A (ko) 2002-10-04
AU2001233979B2 (en) 2004-11-11
NO20024126D0 (no) 2002-08-29
US20030181474A1 (en) 2003-09-25
HK1053111A1 (en) 2003-10-10
LUC00197I1 (index.php) 2021-02-23
JP2003525279A (ja) 2003-08-26
WO2001064656A1 (en) 2001-09-07
FR21C1010I2 (fr) 2022-02-11
CY2021005I2 (el) 2021-06-25
IL150920A0 (en) 2003-02-12
EP1278735B1 (en) 2010-06-30
BR0108879A (pt) 2003-04-29
KR20070106806A (ko) 2007-11-05
IL150920A (en) 2009-08-03
KR100855258B1 (ko) 2008-08-29
CN1416423A (zh) 2003-05-07
NO2021008I1 (no) 2021-02-22
BE2021C507I2 (index.php) 2021-02-26
JP4801335B2 (ja) 2011-10-26
ATE472537T1 (de) 2010-07-15
US6838464B2 (en) 2005-01-04

Similar Documents

Publication Publication Date Title
LUC00197I1 (index.php)
DK1272477T3 (da) Pyrimidinforbindelser
GEP20084357B (en) Pyrimidine derivatives for the treatment of abnormal cell growth
DK1406876T3 (da) 2-anilinopyrimidinderivater som inhibitorer af cyclinafhængige kinaser
GEP20053479B (en) Pyrrolo[2,3-d]Pyrimidine Compounds, Pharmaceutical Composition Containing the Same and Use
GEP20063784B (en) Optical Resolution of (1-Benzyl-4- Methylpiperidin-3-Yl) -Methylamine Enantiomers and Use Thereof for Preparation of Pyrrolo 2,3-Pyrimidine Derivatives as Protein Kinases Inhibitors
BG103195A (en) Substituted indazole derivatives and their application as inhibitors of phosphodiesterase (pde) type iv and of the production of a tumournecrotic factor (tnf)
WO2005037825A3 (en) Protein kinase inhibitors
AU2003297160A1 (en) Benzisoxazole derivatives useful as inhibitors of protein kinases
CA2272705A1 (en) Fused bicyclic pyrimidine derivatives
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
NO20070837L (no) Pyrido-pyrido pyrimidinderivater, fremstilling derav samt terapeutisk anvendelse for behandling av cancer.
CA2461622A1 (en) Substituted benzimidazole compounds and their use for the treatment of cancer
CA2362273A1 (en) Benzazepine-n-ethanoic acid derivatives for treating secondary hypertension
HK1053833A1 (zh) 取代苯基法呢基转移酶抑制剂
MXPA05013050A (es) Derivados de bencimidazol, composiciones que los contienen preparacion de los mismos y usos de los mismos.
MXPA02004441A (es) Derivados de isoxazol como inhibidores de la fosfodiesterasa.
SE0302572D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
AU2001234314A1 (en) Novel phenylheteroalkylamine derivatives
SE0301698D0 (sv) Benzimidazole derivatives, compositions containing them, preparation thereof and uses thereof
SG135051A1 (en) Azaindoles